In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 958-962

  Brvar, Matjaž ^a   Perdih, Andrej ^a   Oblak, Marko ^b   Mašič, Lucija Peterlin ^c   Solmajer, Tom ^a  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b Lek dd   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Antibacterial agents; DNA gyrase enzyme; Drug design; Molecular docking; Virtual screening

Indexed keywords

2 AMINO 4 (2,4 DIHYDROXYPHENYL)THIAZOLE; CYCLOTHIALIDINE; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GYRASE INHIBITOR; NOVOBIOCIN; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; DNA TOPOISOMERASE (ATP HYDROLYSING);

ARTICLE; CALCULATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; MOLECULAR DOCKING; PHARMACOPHORE; THREE DIMENSIONAL IMAGING; BINDING SITE; CHEMISTRY; COMPARATIVE STUDY; DRUG DEVELOPMENT; METABOLISM; PHYSIOLOGY; PROCEDURES; STRUCTURE ACTIVITY RELATION;

BACTERIA (MICROORGANISMS);

BINDING SITES; DNA GYRASE; DRUG DISCOVERY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TOPOISOMERASE II INHIBITORS;

EID: 74049141810     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.060     Document Type: Article

References (34)

1. Brown E.D., and Wright G.D. Chem. Rev. 105 (2005) 759
2. Silver L.L. Biochem. Pharm. 71 (2006) 996
3. Perdih A., Kovač A., Wolber G., Gobec S., and Solmajer T. Bioorg. Med. Chem. Lett. 19 (2009) 2668
4. Maxwell A., and Lawson D.M. Curr. Top. Med. Chem. 3 (2003) 283
5. Maxwell A. Trends Microbiol. 5 (1997) 102
6. Champoux J.J. Annu. Rev. Biochem. 70 (2001) 369
7. Borcherding S.M., Stevens R., Nicholas R.A., Corley C.R., and Self T. J. Fam. Pract. 42 (1996) 69
8. Bradbury B.J., and Pucci M.J. Curr. Opp. Pharm. 8 (2008) 574
9. Oblak M., Kotnik M., and Solmajer T. Curr. Med. Chem. 14 (2007) 2033
10. Boehm H.J., Boehringer M., Bur D., Gmuender H., Huber W., Klaus W., Kostrewa D., Kuehne H., Luebbers T., Meunier-Keller N., and Mueller F. J. Med. Chem. 43 (2000) 2664
11. Tanitame A., Oyamada Y., Ofuji K., Fujimoto M., Iwai N., Hiyama Y., Suzuki K., Ito H., Terauchi H., Kawasaki M., Nagai K., Wachi M., and Yamagishi J. J. Med. Chem. 47 (2004) 3693
12. Charifson P.S., Grillot A.L., Grossman T.H., Parsons J.D., Badia M., Bellon S., Deininger D.D., Drumm J.E., Gross C.H., LeTiran A., Liao Y., Mani N., Nicolau D.P., Perola E., Ronkin S., Shannon D., Swenson L.L., Tang Q., Tessier P.R., Tian S.-K., Trudeau M., Wang T., Wei Y., Zhang H., and Stamos D. J. Med. Chem. 51 (2008) 5243
13. Luebbers T., Anghern P., Gmuender H., and Herzig S. Bioorg. Med. Chem. Lett. 17 (2007) 4708
14. Oblak M., Golic Grdadolnik S., Kotnik M., Jerala R., Filipic M., and Solmajer T. Bioorg. Med. Chem. Lett. 15 (2005) 2507
15. Nakada N., Shimada H., Hirata T., Aoki Y., Kamiyama T., Watanabe J., and Arisawa M. Antimicrob. Agents Chemother. 37 (1993) 2656
16. Nakada N., Gmuender H., Hirata T., and Arisawa M. J. Biol. Chem. 270 (1995) 14286
17. Oram M., Dosanjh B., Gormley N.A., Smith C.V., Fisher L.M., Maxwell A., and Duncan K. Antimicrob. Agents Chemother. 40 (1996) 473
18. Goetschi E., Anghern P., Gmuender H., Hebeisen P., Link H., Masciadri R., and Nielsen J. Pharmacol. Ther. 60 (1993) 367
19. Rudolph J., Theis H., Endermann R., Johannsen L., and Geschke F.-L. J. Med. Chem. 44 (2001) 619
20. Anghern P., Buchmann S., Funk C., Goetschi E., Gmuender H., Hebeisen P., Kostrewa D., Link H., Luebbers T., Masciadri R., Nielsen J., Reindl P., Ricklin F., Schmitt-Hoffmann A., and Theil F.-P. J. Med. Chem. 47 (2004) 1487
21. Qushnie T.P., and Lamb A.J. Int. J. Antimicrob. Agents 26 (2005) 343
22. Plaper A., Golob M., Hafner I., Oblak M., Solmajer T., and Jerala R. Biochem. Biophys. Res. Commun. 306 (2003) 530
23. Lewis R.J., Singh O.M., Smith C.V., Skarzynski T., Maxwell A., Wonacott A.J., and Wigley D.B. EMBO J. 15 (1996) 1412
24. Lafitte D., Lamour V., Tsvetkov P.O., Makarov A.A., Klich M., Deprez P., Moras D., Briand C., and Gilli R. Biochemistry 41 (2002) 7217
25. Schechner M., Sirockin F., Stote R.H., and Dejaegere A. J. Med. Chem. 47 (2004) 4373
26. Kampranis S.C., Gormley N.A., Tranter R., Orphanides G., and Maxwell A. Biochemistry 38 (1999) 1967
27. Rarey M., Kramer B., Lengauer T., and Klebe G. J. Mol. Biol. 261 (1996) 470
28. Wolber G., and Langer T. J. Chem. Inf. Model. 45 (2005) 160
29. Irwin J.J., and Soichet B.K. J. Chem. Inf. Model. 45 (2005) 177
30. 50 values were determined by measuring residual activity at eight (500, 250, 125, 62.5, 31.3, 15.6, 7.8 and 3.9 μM, respectively) different concentrations and represent the concentration of inhibitor where residual activity is 50%.
31. Ryan A.J., Gray N.M., Lowe P.N., and Chung C. J. Med. Chem. 46 (2003) 3448
32. Perdih A., Bren U., and Solmajer T. J. Mol. Model. 15 (2009) 983
33. Barril X., Brough P., Drysdale M., Hubbard R.E., Massey A., Surgenor A., and Wright L. Bioorg. Med. Chem. Lett. 15 (2005) 5187
34. Wenlock M.C., Austin R.P., Barton P., Davis A.M., and Leeson P.D. J. Med. Chem. 46 (2003) 1250